Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating influenza

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating influenza. The composition is prepared from the following components: radix isatidis, honeysuckle stem, radix sophorae tonkinensis, rhizoma paridis, herba houttuyniae, rhizoma dryopteris crassirhizomae, herba artemisiae annuae and radix angelicae dahuricae.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to use of a traditional Chinese medicine composition in preparing medicines for preventing and treating influenza. Background Art

[0002] Influenza is an acute respiratory infectious disease caused by influenza viruses. Influenza viruses are classified into four types: A, B, C, and D, based on differences in their nucleoproteins and matrix proteins. Currently, the main influenza viruses that infect humans are influenza A and influenza B.

[0003] Influenza primarily occurs in crowded places, with winter being the peak season. The elderly, children, and the infirm are particularly susceptible. Influenza has an acute onset, with some experiencing mild symptoms, while others may develop severe complications such as pneumonia. A small number of severe cases progress rapidly, with fatal outcomes resulting from acute respiratory distress syndrome and / or multiple organ failure. High-risk groups such as pregnant women, children, the elderly, and those with chronic illnesses are more susceptible to severe illness from influenza and should take antiviral medications as soon as possible under a doctor's guidance. Summary of the Invention

[0004] In order to improve the treatment of influenza, the present invention provides a use of a traditional Chinese medicine composition in preparing a medicament for preventing and treating influenza.

[0005] The present invention provides use of a traditional Chinese medicine composition in preparing a medicine for preventing and treating influenza. The traditional Chinese medicine composition comprises the following components: isatis root, honeysuckle vine, sophora flavescens root, paridis rhizome, houttuynia cordata, cyperus rotundus, artemisia annua and angelica dahurica.

[0006] In some embodiments of the invention, the influenza comprises influenza A and influenza B.

[0007] In some embodiments of the present invention, the influenza B virus is caused by an influenza B virus.

[0008] In some embodiments of the present invention, the influenza A is caused by influenza A virus H3N2 or H1N1.

[0009] In some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0010] 150-210 parts by weight of Radix Isatidis, 150-210 parts by weight of Caulis Lonicerae, 65-115 parts by weight of Radix Sophorae Tonkinensis, 65-115 parts by weight of Paris Polygoni Multiflori, 240-310 parts by weight of Herba Houttuyniae, 110-160 parts by weight of Cyperus rotundus, 65-115 parts by weight of Artemisia annua, and 65-115 parts by weight of Angelica dahurica.

[0011] In some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0012] 180 parts by weight of Radix Isatidis, 180 parts by weight of Caulis Lonicerae, 90 parts by weight of Radix Sophorae Tonkinensis, 90 parts by weight of Paris Polygoni Multiflori, 270 parts by weight of Herba Houttuyniae, 135 parts by weight of Cyperus rotundus, 90 parts by weight of Artemisia annua, and 90 parts by weight of Angelica dahurica.

[0013] In some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0014] 190 parts by weight of Radix Isatidis, 190 parts by weight of Caulis Lonicerae, 100 parts by weight of Radix Sophorae Tonkinensis, 100 parts by weight of Rhizoma Paris polyphyllae, 250 parts by weight of Herba Houttuyniae, 150 parts by weight of Rhizoma Cyrthospermi, 100 parts by weight of Artemisia annua, and 100 parts by weight of Angelica dahurica.

[0015] In some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0016] 165 parts by weight of Radix Isatidis, 165 parts by weight of Caulis Lonicerae, 105 parts by weight of Radix Sophorae Tonkinensis, 105 parts by weight of Paris Polygoni Multiflori, 250 parts by weight of Herba Houttuyniae, 120 parts by weight of Cyperus rotundus, 100 parts by weight of Artemisia annua, and 80 parts by weight of Angelica dahurica.

[0017] In some embodiments of the present invention, the composition comprises the following components in parts by weight:

[0018] 170 parts by weight of Radix Isatidis, 170 parts by weight of Caulis Loniceraes, 80 parts by weight of Radix Sophorae Tonkinensis, 80 parts by weight of Rhizoma Paris polyphyllae, 290 parts by weight of Herba Houttuyniae, 145 parts by weight of Rhizoma Cyperi, 70 parts by weight of Artemisia annua, and 70 parts by weight of Angelica dahurica.

[0019] In some embodiments of the present invention, the Chinese medicine composition is prepared by the following method:

[0020] Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil for 1-3 times, each time boiling for 1-3 hours; or perform hot reflux extraction for 3-6 hours, combine the decoctions, filter, and concentrate the decoctions to a clear paste at 45-60°C with a relative density of 1.05-1.15. After cooling to room temperature, add ethanol to make the alcohol content 50-70%, stir evenly, and refrigerate for 24-72 hours. Take the supernatant, filter, recover ethanol from the filtrate, and concentrate to an extract at 45-60°C with a relative density of 1.15-1.40. Take the extract, and directly or indirectly add pharmaceutically acceptable excipients through conventional processes to prepare any one of tablets, oral liquids, capsules, granules, and injections.

[0021] In some embodiments of the present invention, the Chinese medicine composition is prepared by the following method:

[0022] Take the above eight herbs, remove impurities and non-medicinal parts, add water and decoct twice, each time for 2 hours; or heat reflux extraction for 3-4 hours, combine the decoctions, filter, and concentrate the decoctions to a clear paste with a relative density of 1.08-1.10 at 50°C, cool to room temperature, add ethanol to make the alcohol content 60%, stir well, refrigerate for 24 hours, take the supernatant, filter, recover ethanol from the filtrate, and concentrate to an extract with a relative density of 1.20-1.35 at 50°C, take the extract, add appropriate amounts of powdered sugar and dextrin, mix well, make granules, dry, make 1000g, and package to obtain granules.

[0023] In some embodiments of the present invention, the granules are honeysuckle cold granules. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Attachment Figure 1 :The efficiency of the composition of the present invention in inhibiting the replication of influenza A virus H3N2

[0025] Attachment Figure 2 :The efficiency of the composition of the present invention in inhibiting the replication of influenza A virus H1N1

[0026] Attachment Figure 3 :The efficiency of the composition of the present invention in inhibiting influenza B virus replication

[0027] Attachment Figure 4 :Efficiency of Lianhua Qingwen Granules in Inhibiting the Replication of Influenza A Virus H3N2

[0028] Attachment Figure 5 :Efficiency of Lianhua Qingwen Granules in Inhibiting Replication of Influenza A Virus H1N1

[0029] Attachment Figure 6 :Efficiency of Lianhua Qingwen Granules in Inhibiting Influenza B Virus Replication

[0030] Attachment Figure 7 :Efficiency of oseltamivir phosphate particles in inhibiting the replication of influenza A virus H3N2

[0031] Attachment Figure 8 :Efficiency of oseltamivir phosphate particles in inhibiting the replication of influenza A virus H1N1

[0032] Attachment Figure 9 :Efficiency of oseltamivir phosphate particles in inhibiting influenza B virus replication DETAILED DESCRIPTION

[0033] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.

[0034] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0035] Example 1: Granules

[0036] Isatis root 180g, honeysuckle 180g, Sophora flavescens 90g, Paris polyphylla 90g, Houttuynia cordata 270g, Cyperus rotundus 135g, Artemisia annua 90g, Angelica dahurica 90g

[0037] Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil twice, each time boiling for 2 hours (or hot reflux extraction for 3-4 hours), combine the decoctions, filter, and concentrate the decoction to a clear paste with a relative density of 1.08-1.10 (50°C), cool to room temperature, add ethanol to make the alcohol content 60%, stir well, refrigerate for 24 hours, take the supernatant, filter, and concentrate the filtrate to an extract with a relative density of 1.30-1.35 (50°C), take 1 part of the extract, add 2-4 parts of sucrose and 1-2 parts of dextrin, mix well, make into granules, dry, make into 1000g, and package.

[0038] Example 2: Tablets

[0039] Isatis root 190g, honeysuckle 190g, Sophora flavescens root 100g, Paris polyphylla 100g, Houttuynia cordata 250g, Cyperus rotundus 150g, Artemisia annua 100g, Angelica dahurica 100g

[0040] Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil twice, each time boiling for 2 hours (or hot reflux extraction for 3-4 hours), combine the decoctions, filter, and concentrate the decoctions to a clear paste with a relative density of 1.08-1.10 (50°C), cool to room temperature, add ethanol to make the alcohol content 60%, stir evenly, refrigerate for 48 hours, take the supernatant, filter, recover ethanol from the filtrate, and concentrate to an extract with a relative density of 1.20-1.35 (50°C), take the extract, add appropriate amounts of starch and dextrin, granulate according to conventional methods, dry, make granules, add appropriate amount of magnesium stearate, tablet, and package to obtain the product.

[0041] Example 3: Capsules

[0042] Isatis root 165g, honeysuckle 165g, Sophora flavescens root 105g, Paris polyphylla 105g, Houttuynia cordata 250g, Cyperus rotundus 120g, Artemisia annua 100g, Angelica dahurica 80g

[0043] Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil twice, each time boiling for 2 hours (or hot reflux extraction for 3-4 hours), combine the decoctions, filter, and concentrate the decoctions to a clear paste with a relative density of 1.08-1.10 (50°C), cool to room temperature, add ethanol to make the alcohol content 60%, stir evenly, refrigerate for 24 hours, take the supernatant, filter, recover ethanol from the filtrate, and concentrate to an extract with a relative density of 1.20-1.35 (50°C), take the extract, add appropriate amounts of starch and dextrin, mix evenly, make granules, dry, whole the granules, make capsules according to conventional methods, and package.

[0044] Example 4: Oral Liquid

[0045] Isatis root 170g, honeysuckle 170g, Sophora flavescens root 80g, Paris polyphylla 80g, Houttuynia cordata 290g, Cyperus rotundus 145g, Artemisia annua 70g, Angelica dahurica 70g

[0046] Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil twice, each time boiling for 2 hours (or hot reflux extraction for 3-4 hours), combine the decoctions, filter, concentrate the decoction to a clear paste with a relative density of 1.08-1.10 (50° C.), cool to room temperature, add ethanol to make the alcohol content 60%, stir evenly, refrigerate for 24-48 hours, take the supernatant, filter, recover ethanol from the filtrate, add water to 900 ml, stir evenly, refrigerate for 24-48 hours, filter, add 0.25% ethyl paraben, stir evenly, filter, add freshly prepared distilled water to 1000 ml, prepare oral solution by conventional methods, each bottle containing 10 ml, sterilize by hot pressure, check for leaks, perform quality inspection, and package.

[0047] Example 5: Injection

[0048] Isatis root 180g, honeysuckle 180g, Sophora flavescens 90g, Paris polyphylla 90g, Houttuynia cordata 270g, Cyperus rotundus 135g, Artemisia annua 90g, Angelica dahurica 90g

[0049] Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil twice, each time boiling for 2 hours (or hot reflux extraction for 3-4 hours), combine the decoctions, filter, concentrate the decoction to a clear paste with a relative density of 1.08-1.10 (50°C), cool to room temperature, add ethanol to make the alcohol content 60-70%, stir evenly, refrigerate for 24-48 hours, take the supernatant, filter, recover ethanol from the filtrate, add water for injection to 900ml, stir evenly, refrigerate for 24 hours, filter, add water for injection to 1000ml, adjust the pH to 5.5-7.5, fill, sterilize at 115°C for 45 minutes, check for leaks, perform quality inspection, print, and package.

[0050] Example 6:

[0051] To demonstrate the inhibitory effect of the composition of the present invention on influenza virus, the granules prepared in Example 1 or commercially available honeysuckle cold granules were used to conduct the following experimental studies:

[0052] 1. Reagents and Materials Used in This Experiment

[0053] (1) Honeysuckle Cold Granules (12g / bag), Positive Control: Lianhua Qingwen Granules (6g / bag), Oseltamivir Phosphate Granules (15mg / bag)

[0054] (2) MDCK and A549 cells

[0055] (3) Viruses: H1N1 (CA04), H3N2, Influenza B virus (B / China / MDCK cell / 2022) Influenza B virus (B / China / MDCK cell / 2022) is OP999337.1 in NCBI's GenBank.

[0056] (4) Cell culture medium: DMEM + 10% FBS + antibiotics (100 U / mL penicillin G, streptomycin sulfate)

[0057] (5) Virus dilution medium: DMEM + antibiotics

[0058] (6) TPCK-Trypsin (final concentration: 2 μg / mL)

[0059] (7) Sterile PBS buffer

[0060] (8) Flat-bottomed 96-well microplates (Corning), 24-well microplates

[0061] (9) RNA extraction kit (Bioer)

[0062] (10) Q-PCR kit (TAKARA)

[0063] (11)CCK8(Biosharp)

[0064] (12) Primers

[0065] 2. Instruments and Equipment Used in This Experiment

[0066] (1) Centrifuge (Thermo Legend™ MACH1.6 / R)

[0067] (2) CO2 cell culture incubator (Thermo Fisher 370 Series)

[0068] (3) Biological safety cabinet (AIRTECH BHC-1604IIA / B3S)

[0069] (4) Microscope and inverted microscope (OLYMPUS CKX31SF)

[0070] (5) Automatic nucleic acid extraction instrument (Bioer)

[0071] (6) Fluorescence quantitative PCR instrument (ABIQuantStudio TM 5)

[0072] (7) ELISA reader

[0073] Specific experimental process (I) Solubility and cytotoxicity of Jindong Ganmao Granules, Lianhua Qingwen Granules, and Oseltamivir Phosphate Granules

[0074] On the first day, after trypsinizing the cells, prepare a cell suspension in DMEM + 10% FBS. Seed approximately 5,000 MDCK or A549 cells per well in a 96-well plate (100 μL / well). The specific number of cells used per well will depend on factors such as cell size and cell proliferation rate. The confluence of the cells should reach approximately 50% on the second day.

[0075] 2. According to the experimental plan, slowly add sterile PBS to the sample until no obvious precipitation occurs, then divide and store at 4 degrees;

[0076] 3. On the second day, rinse the cells twice with DMEM; dilute the drug in DMEM and add it to the cells (100 μL / well). Set up four replicates for each dilution. Use wells containing the corresponding amount of cell culture medium and CCK-8 but no cells as blank controls. Also set up wells containing cells without drug as references. Culture the cells in a CO2 incubator for 24 hours.

[0077] 3. On the third day, observe the cells under a microscope. Add 10 μl of CCK-8 solution to each well and continue incubating in the cell culture incubator for 1 hour. Measure the absorbance at 450 nm using a microplate reader.

[0078] (II) Inhibitory efficiency of Rendong Ganmao Granules, Lianhua Qingwen Granules, and Oseltamivir Phosphate Granules on influenza virus replication at the cellular level

[0079] On the first day, trypsinize MDCK cells and prepare a cell suspension in DMEM + 10% FBS. Inoculate the cell suspension in a 96-well plate (100 μL / well). The cell confluence should reach 80% on the second day.

[0080] 2. On the second day, dilute the drugs and viruses with DMEM. Dilute the drugs in a 2-fold serial dilution, with the starting concentrations being: Rendong Ganmao Granules (REN) 12 mg / mL, Lianhua Qingwen Granules (LIAN) 5 mg / mL, and Oseltamivir Phosphate Granules (Ose) 1 mg / mL; dilute the virus to 200 TCID50 / 100 uL; mix the serially diluted drugs and viruses in equal volumes, at which point the drug concentration is halved, Rendong Ganmao Granules (REN) 6 mg / mL, Lianhua Qingwen Granules (LIAN) 2.5 mg / mL, and Oseltamivir Phosphate Granules (Ose) 0.5 mg / mL, and the virus to 100 TCID50 / 100 uL; incubate at room temperature for 30-60 minutes; perform 8 replicates for each dilution (4 wells for Q-PCR preparation and 4 wells for observing CPE);

[0081] 3. Rinse the cells 3 times with DMEM, add the virus and drug mixture (100uL / well), and culture in a CO2 incubator for 1-1.5 hours; discard the supernatant, and add the serially diluted drug at the same drug concentration;

[0082] 4. After 48 hours, the supernatant was aspirated, RNA was extracted, and changes in viral nucleic acid content were detected by Q-PCR;

[0083] After 72 hours, the cell lesions were observed under a microscope and the number of wells with cell lesions was counted.

[0084] 5. Calculation of results:

[0085] According to the CT value obtained by nucleic acid detection, the percentage (%) of virus inhibition by drugs at different drug concentrations was calculated. The calculation formula is (1-2 -△CT ) × 100% (where ΔCT = CT value of the drug group to be tested - CT value of the virus control group). Based on the statistical number of cytopathic wells, the percentage (%) of virus inhibition by the drug at different drug concentrations was calculated using the formula (1 - number of virus wells / total number of cell wells under the gradient) × 100%.

[0086] The percentage of virus inhibition was used as the ordinate and the logarithm of drug concentration was used as the abscissa, and curve fitting (four parameters) was performed.

[0087] IV. Test and Identification Results (I) Solubility and Cytotoxicity of Rendong Ganmao Granules, Lianhua Qingwen Granules, and Oseltamivir Phosphate Granules

[0088] The dissolution results showed that when REN and LIAN were gradually added to PBS and diluted to 200 mg / mL and 300 mg / mL, respectively, they were suspensions without visible particles. After standing for a period of time, precipitates were still visible. This concentration was the mother solution stored at 4°C. The mother solution was diluted 2-fold using DMEM culture medium. When REN and LIAN were diluted to 6.25 mg / mL and 2.34 mg / mL, respectively, the supernatant began to become clear. Oseltamivir phosphate granules (Ose) were completely dissolved when added to PBS at a concentration of 5 mg / mL. When diluted with DMEM culture medium, the color of the 2.5-0.625 mg / mL culture medium was not pink, and it was speculated that the drug caused a change in pH.

[0089] The cells were observed under a microscope, and the results showed that when the concentration of Rendong Ganmao Granules (REN) was greater than 6.25 mg / mL, no cells could be observed; when the concentration was 6.25 mg / mL or below, cell growth could be observed, and no death of A549 cells and MDCK cells was observed. When the concentration of Lianhua Qingwen Granules (LIAN) was greater than 2.34 mg / mL, no cells could be observed; when the concentration was 2.34 mg / mL or below, cell growth could be observed, and no death of A549 cells and MDCK cells was observed. When the concentration of Oseltamivir Phosphate Granules (Ose) was 2.5 and 1.25 mg / mL, A549 cells and MDCK cells died; at 0.625 mg / mL, the cells did not proliferate and some died; at 0.313 mg / mL, no cell death was observed, and the cells proliferated like untreated cells.

[0090] The CCK-8 kit is a rapid, highly sensitive assay based on WST-8 and widely used for detecting cell proliferation and cytotoxicity. WST-8 is a compound similar to MTT that can be reduced in the presence of the electron coupling reagent 1-Methoxy PMS to produce an orange-yellow, water-soluble formazan. The more and faster the cell proliferation, the darker the color and the higher the OD450 reading. Greater cytotoxicity, the lighter the color and the lower the OD450 reading. For the same cell population, the color depth is linearly correlated with cell number.

[0091] CCK8 was added to detect cell viability, and the results showed that the OD450 values ​​of Rendong Ganmao Granules (REN) and Lianhua Qingwen Granules (LIAN) increased with increasing concentration. Because the drug solution contains insoluble particles, it affects the determination of absorbance values; therefore, this method cannot accurately determine the toxicity of drugs to cells. When the concentration of oseltamivir phosphate granules (Ose) was 2.5 and 1.25 mg / mL, the OD value decreased significantly, indicating that more cells died; at 0.625 mg / mL, compared with the control without drug addition, the OD450 value on MDCK cells did not decrease, and the OD450 value on A549 cells decreased by about 35%; at 0.313 mg / mL, the OD450 value did not decrease significantly. This shows that oseltamivir is non-toxic to MDCK cells at concentrations of 0.625 mg / mL and below, and is non-toxic to A549 cells at concentrations of 0.313 mg / mL and below.

[0092] Based on the above results, it can be considered that the maximum non-toxic concentrations of Rendong Ganmao Granules (REN) and Lianhua Qingwen Granules (LIAN) in A549 and MDCK cells are 6.25 mg / mL and 2.34 mg / mL, respectively, and the maximum non-toxic concentrations of Oseltamivir Phosphate Granules (Ose) in A549 and MDCK cells are 0.313 mg / mL and 0.625 mg / mL, respectively.

[0093] (II) Inhibitory efficiency of Rendong Ganmao Granules, Lianhua Qingwen Granules, and Oseltamivir Phosphate Granules on influenza virus replication in MDCK cells

[0094] 1. Q-PCR detection of the inhibitory efficiency of Rendong Ganmao Granules on influenza virus replication

[0095] The results showed that the honeysuckle granules had an inhibitory effect on the replication of influenza A virus H3N2, H1N1 and influenza B virus in cells (Appendix Figure 1-3 ).

[0096] 2. Q-PCR detection of the inhibitory efficiency of Lianhua Qingwen granules on influenza virus replication

[0097] The results showed that Lianhua Qingwen Granules had an inhibitory effect on the replication of influenza A virus H3N2, H1N1 and influenza B virus in cells (Appendix Figure 4-6 ).

[0098] 3. Q-PCR detection of the inhibitory efficiency of oseltamivir phosphate particles on influenza virus replication

[0099] The results showed that oseltamivir phosphate particles inhibited the replication of influenza A virus H3N2, H1N1 and influenza B virus in cells (Appendix Figure 7-9 ).

[0100] This experimental example shows that the Chinese medicine composition of the present invention has antiviral efficacy against influenza virus and can be used to prepare drugs for preventing and treating influenza, especially for preparing drugs for preventing and treating influenza A (H3N2), influenza A (H1N1) or influenza B.

[0101] The above describes exemplary embodiments of the present invention. It should be understood that the scope of protection of the present invention is not limited to the above exemplary embodiments. Any modifications, equivalent substitutions, improvements, etc. made by those skilled in the art within the spirit and principles of the present invention shall be included in the scope of protection of the claims of this application.

Claims

1. A use of a traditional Chinese medicine composition in preparing a drug for preventing and treating influenza, the traditional Chinese medicine composition comprising the following components: Radix Isatidis, Caulis Lonicerae, Radix Sophorae Tonkinensis, Rhizoma Paridis, Herba Houttuyniae, Rhizoma Cyperi, Artemisia Annua, and Angelica Dahurica.

2. The method according to claim 1, wherein the influenza virus comprises influenza A and influenza B.

3. The method according to claim 2, wherein the influenza B virus is caused by influenza B virus.

4. The method according to claim 2, wherein the influenza A is caused by influenza A virus H3N2 or H1N1.

5. The use according to any one of claims 1 to 4, wherein the composition comprises the following components in parts by weight:

6. The use according to any one of claims 1 to 4, wherein the composition comprises the following components in parts by weight:

7. The use according to any one of claims 1 to 4, wherein the composition comprises the following components in parts by weight:

8. The use according to any one of claims 1 to 4, wherein the composition comprises the following components in parts by weight:

9. The use according to any one of claims 1 to 4, wherein the composition comprises the following components in parts by weight:

10. The use according to any one of claims 1 to 9, wherein the Chinese medicine composition is prepared by the following method: Take the above eight herbs, remove impurities and non-medicinal parts, add water and boil for 1-3 times, each time boiling for 1-3 hours; or perform hot reflux extraction for 3-6 hours, combine the decoctions, filter, and concentrate the decoctions to a clear paste at 45-60°C with a relative density of 1.05-1.

15. After cooling to room temperature, add ethanol to make the alcohol content 50-70%, stir evenly, and refrigerate for 24-72 hours. Take the supernatant, filter, recover ethanol from the filtrate, and concentrate to an extract at 45-60°C with a relative density of 1.15-1.

40. Take the extract, and directly or indirectly add pharmaceutically acceptable excipients through conventional processes to prepare any one of tablets, oral liquids, capsules, granules, and injections.

11. The use according to claim 10, wherein the Chinese medicine composition is prepared by the following method: Take the above eight herbs, remove impurities and non-medicinal parts, add water and decoct twice, each time for 2 hours; or heat reflux extraction for 3-4 hours, combine the decoctions, filter, and concentrate the decoctions to a clear paste with a relative density of 1.08-1.10 at 50°C, cool to room temperature, add ethanol to make the alcohol content 60%, stir well, refrigerate for 24 hours, take the supernatant, filter, recover ethanol from the filtrate, and concentrate to an extract with a relative density of 1.20-1.35 at 50°C, take the extract, add appropriate amounts of powdered sugar and dextrin, mix well, make granules, dry, make 1000g, and package to obtain granules.

12. The use according to claim 11, wherein the granules are honeysuckle cold granules.

Images